i wish the company would send us an update

should end up above a penny soon

what's up, still holding here

$GYST It is important to mention that the company is committed to environmental sustainability and a clean energy approach. The co-location we have engaged generates its power from a nuclear power plant, thereby allowing the Company's equipment to be powered by a zero-emission clean energy source. This business decision is in-line with our values and represents a mindful step on our journey to be a net-zero climate impact mining operation.

$GYST Due to extremely high demand, we are planning to dedicate some of the equipment and space we have acquired to subleasing to 3rd party clients. This business model will provide supplemental revenue in addition to mining BTC for ourselves.

$GYST Graystone Company, Inc. (OTC: GYST) is pleased to announce the successful expansion of its bitcoin mining operations. Just two weeks after placing an order for 10 units of S19j Pro (100 TH/S) we were able to secure the purchase of 15 additional machines, thereby, increasing the number of units purchased to 25 total. This new equipment is scheduled for December delivery and is expected to be installed in January 2022. The cost to host the units is estimated at $185 per unit per month. Once the new equipment is installed and operational, the Company is expected to generate the following:

Yearly Revenue*: $487,756
Yearly Expenses for machines*: $82,536
Yearly operational profit*: $405,220

$GYST Graystone Company operates two divisions: A Bitcoin BTC mining operation and a Wellness, Longevity and Anti-Aging product line. The Graystone Company, Inc. (OTC PINK:GYST) is headquartered in Fort Lauderdale, FL., and can be contacted at www.thegraystonecompany.com or by phone at (954) 271-2704.

$GYST We strongly believe that our current focus needs to be at building a strong foundation for the company and we try to utilize any additional revenue accordingly – ramping up purchase orders and stretching every dollar to get us maximum TH/S that our budget allows. So far this approach has proven to work very effectively for us, helping us to exceed our projected goals every month and we are looking forward to building a bright tomorrow for our Company and supportive shareholders.

$GYST The company has set the goal and expects its revenues to increase by 70% for the month of November 2021, totaling approximately $98,000. We anticipate that strengthening of bitcoin market will support our projection and we plan to have sufficient funds at the end of the month to increase our purchase order for new mining equipment.

$GYST Graystone has proven its exponential growth since the launch of its mining division in May 20, 2021. Each month we exceeded our projected goals and we are pleased with the mining results and the pace of our expansion.

$GYST Graystone Company, Inc. (OTC: GYST) announced today that preliminary results for the total unaudited revenues increased to approximately $58,000 in October 2021, representing a staggering increase of 1,568%.

great news and shares structure $OTLC has nowhere to go but up

more interest coming here

$OTLC "The ground work laid down for IL-2 and PD-1 will serve as the foundation of future strategic alliances to include CAR-T and Vaccine." said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

$OTLC PD-1: Multiple phase 2 trials combination of OT-101 with a PD-1 inhibitor in collaboration with a top-five pharmaceutical company. The participating members of this consortium will be disclosed in future dates when allowed. Trials scheduled to initiate throughout 2021-2022. Of note is the biomarker program spanning mesothelioma, glioblastoma, lung, and colorectal cancers where AI driven transcriptome analyses will be used to derived the predictive biomarker for TGF-ß therapeutics including OT-101.

$OTLC Ongoing OT-101-ONC trials

IL-2: Phase 1b trial combination of OT-101 with IL-2 (Proleukin®?, Aldesleukin) in collaboration with Clinigen Group and ABIO. Trial scheduled to completed in 2020.

$OTLC The OT-101-ONC program is designed to assess the impact of OT-101 across multiple cancer indications where local tumoral secretion of TGF-ß suppressed the clinical activity of checkpoint inhibitors, CAR-T, and vaccine. The OT-101-ONC program has been moving forward steadily through strategic alliance with top pharmaceutical companies. OT-101-ONC program was expanded to include mesothelioma, melanoma, glioblastoma, and pancreatic cancer.

$OTLC On October 18, Data lock and SDTMs & ADaMS Databases were generated for Phase 2 C001 Covid Study: “A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study of OT 101 in Hospitalized COVID-19 Subjects”. The top line data will be reported when data analysis is completed.

$OTLC Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-ß therapeutics for oncology and virology today announced an update on the Phase 2 C001 Covid Study and the OT-101-ONC program for the potential first-in-class investigational TGF-ß immunotherapy, OT-101, in difficult-to-treat cancers.

$OTLC There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD - however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore there is an urgent need for effective therapy against FSD and HSDD.

$OTLC Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260–269).

HSDD is characterized by a low sexual desire, that causes marked distress or interpersonal difficulty, and is not due to a co-existing medical or psychiatric condition, problems within the relationship or the effects of a medication or other drug substance. HSDD affects approximately 5.8 million U.S. premenopausal women (1 in 10 premenopausal women). Almost 98%, approximately 5.7 million of affected premenopausal women are not on any therapy for HSDD, either due to lack of education or lack of therapies available. One in 10 premenopausal women have low desire with associated distress.

$OTLC The percentages of men affected by ED are as follows: 14.3-70% of men aged ≥60 years, 6.7-48% of men aged ≥70 years, and 38% of men aged ≥80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors.

$OTLC ED is the most prevalent male sexual disorder globally. The market will continue to grow due to increased vascular disorders followed by the aging population across the world. Furthermore, rising psychological problems, followed by chronic diseases like diabetes, alcohol, and smoking habits are also considered as one of the major driving factors for the growth of the market. Oral PDE5 inhibitors, especially Viagra, Cialis, and Levitra, dominated the market with around US$3.8 billion of revenue in 2020.

$OTLC On May 2020, KYNMOBI™? (apomorphine HCI) sublingual film developed by Sunovion Pharmaceuticals was approved through the 505(b)2 pathway for acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) dissolves under the tongue. Per Suniovion Pharmaceuticals, KYNMOBI is expected to generate $219 million annually. https://www.pharmaceutical-technology.com/comment/sunovion-pharmaceuticals-kynmobi-parkinsons/

$OTLC Over 60,000 new patients being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately 10 million suffer from this disease globally. https://www.parkinson.org/Understanding-Parkinsons/Statistics.

$OTLC "The acquisition of AL-101, expands Oncotelic’s product portfolio to the fast to market 505(b)2 regulatory pathway. AL-101 has many of the same properties necessary to replicate the successes I had with the 505(b)2 route for Abraxane at Abraxis and Cynviloq at Igdrasol. I am impressed with its marked improvement on quality of life for PD patients and look forward to working with pts and healthcare professionals in PD.” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

$OTLC Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101 (intranasal apomorphine). Oncotelic intends to develop AL-101 via fast-to-market 505(b)2 regulatory pathway for Parkinson Disease (“PD”) and Erectile Dysfunction (“ED”), especially phosphodiesterase 5 (“PDE5”) non-responders. AL-101 will also be developed as a new drug against Female Sexual Dysfunction (“FSD”), including Hypoactive Sexual Desire Disorder (“HSDD”). AL-101 has a favorable safety and efficacy profile and is phase 3 ready with six clinical trials completed and over 200 patients (2,200 doses) treated.

$OTLC Assessments of safety and efficacy variables were performed as per the study protocol. The final visit end of study (EOS) was on Day 28. Serious AEs were followed-up until they resolve or get stabilized or until 30 days from the subject’s involvement in the study had ended, whichever occurred first, and it was documented according to ICH-GCP and Indian GCP guidelines

Over all 122 patients were screened. The subjects were randomly assigned to one of the two groups: Artemisinin 500 mg (BD) with SOC or SOC in a ratio of 2:1.

Subjects were initially hospitalized for 5 days of study treatment in both treatment arms. When necessary, subjects were permitted to remain for a few more additional days in the hospital for the second cycle or third cycle of treatment.

$OTLC The subjects were randomly assigned and received treatment with either the test plus SOC (n=80) or the SOC (n=41). After having obtained signed, written Informed Consent, these subjects had undergone a screening examination. Provided all inclusion/exclusion criteria were fulfilled, the subjects were enrolled and randomized by block randomization to one of the two treatment arms on Day 1. All the subjects had received the usual treatment according to ICMR (Indian Council of Medical Research) and other Indian ministry of healthcare guidelines.

$OTLC NCT05004753- A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19. This was an open label, prospective, multicenter study. Subjects with a clinical diagnosis of mild to moderate COVID-19, subject to fulfilling other inclusion and exclusion criteria, were randomized to receive either SOC or test drug Artemisinin 500 mg capsule/day for 5 days + standard of care (SOC) per cycle with the option to repeat as needed until symptoms of the disease are resolved, up to a total of 3 cycles (“5 days treatment, 5 days off" comprise a cycle) or standard of care (SOC).

$OTLC In summary, based on the study results, it was shown that Artemisinin 500 mg capsule administered once daily for 5 days:

was effective in treating subjects with mild and moderate COVID-19,
artemisinin+SOC group showed significant improvement over SOC in WHO severity scale on Day 4 and Day 5 with p=0.0045 and p=0.0370, respectively.
decline in body temperature was faster and higher in Artemisnin+SOC group by day 2 in comparison to SOC arm,
improvement in respiratory rate was faster and higher in Artemisnin+SOC group by day 5 in comparison to SOC arm,
improvement in mean SpO2 level was significantly higher in Artemisnin+SOC group by day 28 (end of study) in comparison to SOC arm (p=0.029),
no clinically significant changes in biochemistry or hematology parameters,
was safe and well-tolerated by the study subjects.

$OTLC "The positive outcome of this well conducted clinical trial has validated our TGF-ß platform against COVID-19. Targeting the immutable host protein, PulmoHealTM/ ArtiVedaTM is effective against COVID-19 variants. We look forward to continuing expansion of our marketing of PulmoHealTM/ ArtiVedaTM as phytomedicine and further clinical development of Artemisinin as a pharmaceutical." said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

$OTLC Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-ß therapeutics for oncology and COVID-19, reported today that PulmoHealTM/ ArtiVedaTM has proven active against mild and moderate COVID-19 following the preplanned prospective analysis of ARTI-19 clinical trial (NCT05004753- A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19). The study report will serve as the basis for Oncotelic’s regulatory submission for marketing approval of PulmoHealTM/ ArtiVedaTM.

$OTLC Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. ("PointR") in November 2019. The PointR Acquisition was intended to create a publicly traded

$OTLC Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers.

$OTLC Oncotelic is artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-ß immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-ß RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients.

$OTLC Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020.

$OTLC "This latest development is a continuation of our relationship with GMP, which started early 2020 when GMP began invested in Oncotelic COVID-19 programs. Being fully capitalized we look forward to rapid progress in bringing needed therapies to patients in both oncology and COVID-19. A robust IPO comparable to similar IPOs would be a strong win for Oncotelic’s shareholders who have been unwavering in their support for finding the cures for these debilitating diseases." said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

$OTLC Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-ß therapeutics for oncology and COVID-19 and Golden Mountain Partners, (“GMP”) announced that they are forming a joint venture (“JV”) to advance clinical development of Oncotelic’s pharmaceutical pipeline and build out of manufacturing facilities for the commercial launch of Oncotelic’s drug candidates. The JV is expected to be taken to an initial public offering (“IPO”). Recent IPOs for TGF- ß assets include Genor Biopharma, Pliant Therapeutics and ScholarRock. The Company and GMP signed a term-sheet, which amongst other requirements, includes moving into a standstill agreement and an immediate infusion of $1.5 Million by GMP into Oncotelic.

$BLBX Blackbox is a SaaS company with a growing base of users that spans 42 countries; current subscription fees are $99.97 per month or $959.00 annually. $SCHW $HOOD $SOFI $MS $JPM $BAC